Permanent Neonatal Diabetes Mellitus Caused by a Novel Homozygous (T168A) Glucokinase (GCK) Mutation: Initial Response to Oral Sulphonylurea Therapy
- 31 July 2008
- journal article
- case report
- Published by Elsevier BV in The Journal of Pediatrics
- Vol. 153 (1), 122-126
- https://doi.org/10.1016/j.jpeds.2007.12.037
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Switching from Insulin to Oral Sulfonylureas in Patients with Diabetes Due to Kir6.2 MutationsThe New England Journal of Medicine, 2006
- Activating Mutations in the Gene Encoding Kir6.2 Alter Fetal and Postnatal Growth and Also Cause Neonatal DiabetesJournal of Clinical Endocrinology & Metabolism, 2006
- Activating Mutations in the Gene Encoding the ATP-Sensitive Potassium-Channel Subunit Kir6.2 and Permanent Neonatal DiabetesThe New England Journal of Medicine, 2004
- Structural Basis for Allosteric Regulation of the Monomeric Allosteric Enzyme Human GlucokinaseStructure, 2004
- Neonatal Diabetes Mellitus Due to Complete Glucokinase DeficiencyThe New England Journal of Medicine, 2001
- Transient neonatal diabetes: widening the understanding of the etiopathogenesis of diabetes.Diabetes, 2000
- Mutants of glucokinase cause hypoglycaemia- and hyperglycaemia syndromes and their analysis illuminates fundamental quantitative concepts of glucose homeostasisDiabetologia, 1999
- Insulin promoter factor-1 gene mutation linked to early-onset type 2 diabetes mellitus directs expression of a dominant negative isoprotein.JCI Insight, 1998
- Aetiopathology and genetic basis of neonatal diabetesArchives of Disease in Childhood: Fetal & Neonatal, 1997
- Human glucokinase gene: isolation, characterization, and identification of two missense mutations linked to early-onset non-insulin-dependent (type 2) diabetes mellitus.Proceedings of the National Academy of Sciences of the United States of America, 1992